Cardiac Science slowdown
This article was originally published in The Gray Sheet
Automated external defibrillator maker reports $36.1 million in revenue for the second quarter, down 30% from Q2 2008, in a pre-earnings announcement Aug. 3. Revenue is also down about $3 million from last quarter, when the company complained of a soft capital equipment market and changes in Japan's AED market. Cardiac Science said it has withheld shipments of about $3 million in AED products since late June in order to "evaluate the quality of certain components." The firm has not yet determined when shipping might resume, but will update investors during its Aug. 10 earnings call
You may also be interested in...
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.